Stay updated with breaking news from குடும்ப குறுகிய. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
How much sleep do you need? It's all in the genes. labroots.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labroots.com Daily Mail and Mail on Sunday newspapers.
ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share this article PANGYO, GYEONGGI PROVINCE, Korea, Jan. 29, 2021 /PRNewswire/ SK Biopharmaceuticals announced that the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of cenobamate for the adjunctive treatment of focal-onset (partial-onset) seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-seizure medications (ASMs). The European Commission (EC), which is authorized to approve medicines in the European Union, is expected to issue its decision within approximately 67 days of receipt of the CHMP opinion. SK Biopharmaceuticals and Arvelle Therapeutics entered into a licensing agreement in 2019 for Arvelle to commercialize SK Biopharmaceuticals cenobamate in Europe. Cenobamate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of partial-onse ....